U.S. Oil and Gas Stock News

BrightView earnings reaction and what it means for investors BrightView Holdings (BV) recently reported Q1 revenue growth of 6.1% year on year, topping analyst expectations by 8.9%, while adjusted operating income lagged estimates and full-year guidance came in weaker than peers. Even so, the stock has risen 5% since the release. This suggests that investors are currently putting more weight on the revenue outperformance than on the profitability shortfall or softer outlook. See our latest...

Earlier this month, Silgan Holdings Inc.’s Board of Directors declared a quarterly cash dividend of US$0.21 per share, payable on June 15, 2026 to shareholders of record on June 1, 2026. This dividend decision highlights management’s commitment to ongoing cash returns even as the company contends with high production costs and constrained free cash flow. Next, we’ll examine how maintaining this dividend amid tight margins could influence Silgan Holdings’ investment narrative and future...

Euronet Worldwide recently reported a strong first quarter, with US$1.01 billion in revenue exceeding analyst expectations and underscoring progress across its global payments and money transfer operations. At its May 20, 2026 Investor Day, the company outlined a shift toward a unified global payments platform emphasizing digital channels, shared technology, and increased capital allocation to buybacks and acquisitions. Now we will explore how Euronet’s digital-first repositioning and...

Recent performance snapshot Uniti Group (UNIT) has drawn fresh attention after a mixed run in the stock, with the price around $11.04 and recent returns ranging from a decline over the past month to gains over the past 3 months and year to date. See our latest analysis for Uniti Group. The share price has cooled in the past month, down 7.85%, but that comes after a strong 90 day share price return of 36.97% and a 3 year total shareholder return of 115.83%. This suggests momentum has been...

Earlier in 2026, SiteOne Landscape Supply held its annual meeting, where shareholders elected William W. Douglas III and Jeri L. Isbell to one-year board terms, ratified Deloitte & Touche LLP as auditor for the 2026 fiscal year, and approved the advisory vote on executive compensation. On the same day, SiteOne reported first-quarter 2026 results that included a net loss and revenue below expectations, a combination that sharpened investor attention on how effectively its growth and margin...

Kosmos Energy (KOS) recently reported record quarterly and daily production, updated its full year production growth outlook, and set a higher debt reduction target, drawing fresh attention to the stock’s risk and reward profile. See our latest analysis for Kosmos Energy. The stock’s recent 1-day and 7-day share price returns, down 2.9% and 6.2%, contrast with a 30-day share price return of 7.8% and a 90-day gain of 47.1%. The 239.4% year to date share price return and mixed longer term total...

In May 2026, S&P Global Inc. reported strong fiscal 2025 results, approved a second‑quarter cash dividend of US$0.97 per share, and advanced the planned spin‑off of its Mobility division into Mobility Global Inc., while shareholder proposals on special meeting thresholds and charitable giving reports were voted down at the annual meeting. The decision to separate the Mobility business, supported by a US$2.00 billion private notes offering and a US$500.00 million credit facility, signals a...

Recent commentary around MasTec (MTZ) focuses on its strong sales pipeline, expectations for faster sales growth, and earnings per share that exceeded peers, along with fund interest related to AI-capable data center infrastructure spending. See our latest analysis for MasTec. Despite a recent pullback, with the 7 day share price return down 7.9% and the 1 day share price return down 1.7%, MasTec’s 90 day share price return of 37.2% and 1 year total shareholder return of 150.7% point to...

CG Oncology recently reported positive first results from its Phase 2 CORE-008 Cohort CX trial, showing encouraging high-grade event-free survival, high complete response rates, and a favorable safety profile for intravesical cretostimogene grenadenorepvec plus gemcitabine in high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer, with data presented at the 2026 AUA meeting. An interesting aspect is that more than 80% of patients were treated in community practices,...

NVIDIA (NVDA) just reported record quarterly results, paired with a 25x dividend increase to US$0.25 per share and a new US$80b buyback. This puts capital returns and AI growth firmly in focus for shareholders. See our latest analysis for NVIDIA. Despite a slight pullback around the results, with the share price down 1.9% over the last day and 4.4% over the past week, NVIDIA still shows firm momentum, with a 30 day share price return of 3.4% and a 1 year total shareholder return of 64.1% on...

Norwegian Cruise Line Holdings recently reported first-quarter results that exceeded its own guidance and consensus estimates, outlined US$125 million in SG&A run-rate savings, and entered a cooperation agreement with activist investor Elliott Management that reshaped its board and governance oversight. At the same time, directors Jonathan Z. Cohen and Jose E. Cil purchased tens of thousands of shares on the open market, even as a law firm announced an investigation into potential...

In the past quarter, Hancock Whitney reported first-quarter 2026 adjusted earnings per share of US$1.52, ahead of expectations, as higher net interest income and modest loan growth helped offset a restructuring loss in its securities portfolio and a drop in non-interest income. Alongside these results, management outlined a 2026 outlook calling for modest growth in loans, deposits, and net interest income, while also filing a Form 144 for proposed insider share sales tied to 2020 stock...

The latest review by the independent Data Safety Monitoring Committee of EyePoint (EYPT) pivotal Phase 3 DURAVYU program kept both LUGANO and LUCIA trials on course, with interim masked data indicating a continued favorable safety profile. See our latest analysis for EyePoint. EyePoint’s recent safety update for DURAVYU comes after a sharp share price pullback this year, with the stock down 26.03% on a year to date share price return but still showing a 127.64% total shareholder return over...

It looks like Brookfield Infrastructure Corporation ( NYSE:BIPC ) is about to go ex-dividend in the next 4 days. The...

It's been a good week for Vipshop Holdings Limited ( NYSE:VIPS ) shareholders, because the company has just released...

Fastly recently reported strong growth in its Compute and Observability business, highlighting surging demand for AI-powered workloads at the edge and expanded customer co-innovation on complex use cases. A series of insider share sales in recent months, largely tied to tax obligations and pre-arranged trading plans, underscores that recent management transactions appear compensation-related rather than signaling operational change. Next, we’ll examine how Fastly’s accelerating AI-driven...

NervGen Pharma (NGEN) has drawn fresh attention after completing a follow on public equity offering of approximately $60 million, including common shares and warrants, to fund its neuroreparative drug development programs. See our latest analysis for NervGen Pharma. The follow on offering has coincided with sharp share price pressure, with NervGen Pharma’s 1 day share price return down 43.48% and its year to date share price return down 64.63%. This comes even though the 5 year total...

Earlier this week, Cardinal Health reported that quarterly revenue rose 11% year on year to US$60.94 billion, missing analysts’ revenue forecasts but beating full-year earnings-per-share guidance. Management highlighted the durability and resilience of the business, pointing to growth in its specialty portfolio, stronger free cash flow guidance for fiscal 2026, and ongoing share repurchases as key supports for its longer-term outlook. With Cardinal Health boosting free cash flow guidance and...

Gibraltar Industries (ROCK) is back on investors’ radar after a recent share price move, with the stock closing at US$37.18 as its recent performance and fundamentals draw closer attention. See our latest analysis for Gibraltar Industries. The recent 4.61% 1 day share price return and 5.09% 7 day share price return sit against a much weaker backdrop, with the 1 year total shareholder return down 37.07% and the 5 year total shareholder return down 53.20%. This suggests that recent momentum is...

In May 2026, Valley National Bancorp completed a US$500.00 million fixed‑to‑floating subordinated notes offering, announced the full redemption of its US$300.00 million 3.00% subordinated notes due 2031, and affirmed a quarterly common dividend of US$0.1100 per share payable on July 1, 2026. Together with board approvals, director equity grants, and a refreshed corporate social responsibility report, these capital and governance moves outline how Valley is reshaping its funding mix while...

Earlier this week, East West Bancorp filed two shelf registrations totaling US$483.76 million for ESOP-related common stock offerings and granted routine stock awards to non-employee directors following its 2026 Annual Meeting. Shareholders also endorsed all governance proposals, including refreshed stock incentive and employee stock purchase plans, signaling strong support for management’s long-term capital and compensation framework. With shareholders backing new stock plans and...

Earlier in May 2026, UroGen Pharma reported new Phase 3 data showing UGN-103 achieved a 94.5% six-month durability of response in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, closely mirroring outcomes seen with its approved intravesical therapy ZUSDURI. The company also highlighted long-term durability results for ZUSDURI and outlined plans to file an NDA for UGN-103 in the third quarter of 2026, aiming to expand its RTGel-based bladder cancer franchise and...

Kymera Therapeutics (KYMR) is back in focus after showcasing expanded Phase 1b data for KT-621, its oral STAT6 degrader, at major dermatology and respiratory conferences. The company highlighted clinical signals in atopic dermatitis and asthma. See our latest analysis for Kymera Therapeutics. Despite the recent KT-621 data spotlight, Kymera Therapeutics’ share price has eased in the near term, with the 30 day share price return down 7.09% and the 90 day share price return down 10.79%. At the...

VinFast Auto (NasdaqGS:VFS) is back in focus after outlining plans to sell two factories in Vietnam to cut about US$6.9b of debt, alongside rolling out upgraded electric SUVs and expanding global after-sales support. See our latest analysis for VinFast Auto. The recent factory sale plan, upgraded VF 8 and VF 9 launches, and global service push arrive after a mixed run for investors. The share price is at US$3.57, with a 30 day share price return down 18.12%, a 90 day share price return up...